BTZ043 Racemate is primarily investigated for its potential in the treatment of tuberculosis (TB), particularly drug-resistant strains. It acts as an inhibitor of decaprenylphosphoryl-β-D-ribose 2′-epimerase (DprE1), a key enzyme involved in the biosynthesis of the mycobacterial cell wall. By targeting this enzyme, it disrupts the cell wall formation, leading to the death of Mycobacterium tuberculosis. Its racemic form is studied to understand its efficacy and optimize its therapeutic potential. Research focuses on its use as a lead compound for developing novel anti-TB drugs, especially in combination therapies to combat multidrug-resistant and extensively drug-resistant TB.